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Abstract
Cells cope with the threat of xenobiotic stress by activating a complex molecular network
that recognizes and eliminates chemically diverse toxic compounds. This “chemoimmune
system” consists of cellular Phase I and Phase II metabolic enzymes, Phase 0 and Phase
III ATP Binding Cassette (ABC) membrane transporters, and nuclear receptors regulating
these components. In order to provide a systems biology characterization of the chemoim-
mune network, we designed a reaction kinetic model based on differential equations de-
scribing Phase 0–III participants and regulatory elements, and characterized cellular fitness
to evaluate toxicity. In spite of the simplifications, the model recapitulates changes associat-
ed with acquired drug resistance and allows toxicity predictions under variable protein ex-
pression and xenobiotic exposure conditions. Our simulations suggest that multidrug ABC
transporters at Phase 0 significantly facilitate the defense function of successive network
members by lowering intracellular drug concentrations. The model was extended with a
novel toxicity framework which opened the possibility of performing in silico cytotoxicity as-
says. The alterations of the in silico cytotoxicity curves show good agreement with in vitro
cell killing experiments. The behavior of the simplified kinetic model suggests that it can
serve as a basis for more complex models to efficiently predict xenobiotic and drug metabo-
lism for human medical applications.
Introduction
Living organisms are permanently exposed to potentially toxic xenobiotic compounds includ-
ing environmental toxins and also drugs administered for therapeutic purposes. Although tis-
sue barriers, such as the skin, the intestinal epithelia or the blood brain barrier limit the entry
of xenobiotics into the body or a specific organ, individual cells have to cope with significant
xenobiotic stress. The majority of the xenobiotics are detoxified through the canonical Phase I,
II, and III pathways [1–5]. Phase I pathways include oxidative, reductive and hydrolysis
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reactions. The most prominent Phase I enzymes belong to the cytochrome P450 (CYP) family.
CYPs (e.g. CYP3A4, CYP3A5, CYP2D6, CYP1A1, CYP1B1 and CYP2E1) recognize a wide
range of chemicals as substrates, usually converting them into a more water soluble form [6].
The oxidized intermediates are further metabolized by the action of Phase II enzymes (e.g.
UDP-glucuronosyltransferases—UGTs, glutathione S-transferases—GSTs), which neutralize
Phase I products by conjugating them with small molecules [7]. Finally, conjugates are re-
moved from the cells to avoid untoward accumulation. Phase III elimination is mostly linked
to the activity of ABC (ATP Binding Cassette) transporters, including MRP1/ABCC1 and
MRP2/ABCC2 [8, 9]. Additional ABC transporters (such as MDR1/ABCB1 and BCRP/
ABCG2) can recognize unmodified xenobiotics and extrude them from the cell (or already
from the cell membrane) in the so-called Phase 0 reaction, thus reducing the load on the entire
metabolic process [4, 10].
The expression of phase 0-III enzymes and transporters is orchestrated by several nuclear
receptors and transcription factors (e.g. NR1I2/PXR—pregnane X receptor, NR1I3/CAR—
constitutive androstane receptor, and AhR—aryl hydrocarbon receptor) that recognize xenobi-
otics and often also their metabolites as ligands [1]. These regulatory processes converge to se-
lect for the most efficient set of proteins to protect the cell from the given xenobiotic. Based on
the similarities of the cellular detoxification processes and the immune system (e.g. regulator
and effector elements, differentiation of metabolites from xenobiotics (“self” vs. “nonself”, etc.),
the complex network underlying cellular detoxication has been referred to as the “chemoim-
mune system” [4].
Therapeutic compounds are subject to cellular metabolism that influences both the ADME-
Tox (absorption, distribution, metabolism, excretion, and toxicity) properties of drugs and also
the drug-drug interactions [4, 9]. In many cases, metabolites may be more influential than par-
ent xenobiotics. For example, it is estimated that three quarters of the carcinogens are activated
from parent procarcinogenes by CYPs [11]. Conversely, bioactivation of prodrugs is desirable.
Cyclophosphamide is activated by CYP to form its pharmacologically active phosphoramide
mustard metabolite [12, 13]. Similarly, morphine-6-glucuronide produced by UGTs from mor-
phine is a more potent analgesic than morphine itself [14]. Although the pharmacological rele-
vance of the chemoimmune system is universally appreciated, little is known about the
interplay of the individual enzymes or the kinetic parameters of the regulatory mechanisms. To
fully appreciate the complexity of this elaborate system, dynamic interactions between the par-
ticipating enzymes should be considered [15].
Mathematical models are promising possibilities for the investigation of such elaborate sys-
tems. On the other hand, xenobiotics interact with many regulators, enzymes and transporters,
but the kinetic parameters describing these reactions are often unknown. Thus the formulation
of widely applicable, general models is a serious challenge. Recent attempts to model the detox-
ifying cascade followed a single, well characterized xenobiotic or focused only on limited as-
pects of cellular detoxication. Stamatelos et al. created models describing the metabolism of
arsenic compounds. While their toxicokinetic model [16] describes only Phase I-III reactions,
the combined toxicokinetic-toxicodynamic model [17] includes also a simple transcriptional-
translational feedback loop in the form of the Keap1–Nrf2 pathway playing a role in oxidative
stress response regulation [18]. The electrophilic stress response model of Zhang and Andersen
confines itself only to Phase II-III reactions, but contains more details about the Keap1–Nrf2
pathway [19]. Up to now, probably the model of Zhang et al. covers most aspects of cellular de-
toxication [20]. Beside Phase I-III reactions and the Keap1–Nrf2 pathway (the latter is de-
scribed by not only feedback but also by feedforward loops) it contains regulatory circuits
based also on the AhR nuclear receptor. However, since this model is geared towards mecha-
nisms underlying overcompensation by the homeostatic control systems, especially hormetic
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response, and since the applied simplifications, it is suboptimal for more general modeling of
the chemoimmune system.
To be able to study the role of each metabolite, enzyme and reaction involved in cellular de-
toxication in the context of this complex network, we generalized and extended the scheme
proposed by Zhang et al. to create a more comprehensive model. We introduced ABC0 as a
transporter modeling Phase 0 efflux transporters operating at pharmacological barriers. Fur-
thermore, by making a clear distinction between xenobiotic metabolites and reactive species
produced by the endogenous metabolic processes of the cell, we were able to analyze their rela-
tive importance. Using time course simulations we demonstrated our model’s ability to recapit-
ulate elementary properties of the chemoimmune system. In addition, we introduced a novel
framework to describe the effects of toxic species on cellular fitness. This opened the possibility
for the calculation of in silico cytotoxicity curves resembling experimentally obtained results.
Our results of in silico toxicity analysis are in agreement with RNA silencing experiments de-
scribed in the literature [21, 22].
Methods
Generation of the model
The SBML (Level 2 Version 4) model format [23] was chosen for the implementation of the
model. The model was created by using the graphical user interface of COPASI (version 4.8),
the biochemical network simulator package [24] and custom Python scripts employing
libSBML programming library (version 5.8.0) [25]. Time course simulations were carried out
in COPASI, through its Python bindings. For numerical integration the deterministic
(LSODA) solver was applied along with its default settings. Typically, the duration of the simu-
lations was 60 hours with an interval size of 60 seconds. Initial conditions (here: concentra-
tions) for time course simulations were steady state conditions corresponding to the given
parameter set, and to zero extracellular xenobiotic concentration ([Xe]). The initial conditions
were calculated by running a preliminary, 30 day long time course simulation, sufficient for the
system to reach steady state. Details of the model are provided as Supporting information.
Biological and chemical details of the model
The chemoimmune network model is based on the scheme proposed by Zhang et al. [20],
which describes the metabolism of xenobiotic X including the following reactions:
Phase I CYP oxidizes X to X’, Phase II GST conjugates GSH to X’ forming X”, which in turn
is excreted from the cell by a membrane transporter (MRP). Transcription and translation of
the participating enzymes are regulated by the AhR nuclear receptor and the Nrf2 transcription
factor. The model contains three compartments: the extracellular space, the cytoplasm and the
nucleus. In order to create a model tailored to the study of the chemoimmune system, this ini-
tial scheme was significantly modified (S1 Fig.). In brief, the following changes were
introduced:
(1) ABC0, a Phase 0 transporter which is capable to eliminate the cytoplasmic form of X
(Xc) from the cell was introduced. (2) The transcriptional and translational regulation of ABC0
was added to the scheme. (3) Some parameters were altered to obtain biologically more realistic
concentration ranges. For example the transcription rate constant of ABCIII (a general Phase
III ABC transporter; formerly MRP) was reduced to decrease its level, while the transportation
rate constant of X”c was increased to keep its transportation rate roughly unaltered. For mathe-
matical details of the model see S1 Model and S1–S4 Tables. (4) Reactive species originating
from background reactions (X’bc) and its conjugated form (X”bc) were introduced (see Results
for rationale). X’bc and X”bc were treated as respective xenobiotic metabolites X’c and X”c. X’c
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and X’bc are substrates of GST, while X”c and X”bc are substrates of ABCIII. To avoid extremely
complex enzyme kinetics functions describing the metabolism of these two pairs of alternative
substrates, instead of using conventional competitive inhibition formulae the following simpli-
fication was applied. In equations describing conjugation by GST and transport by ABCIII, the
total enzyme amount was divided according to the concentration ratios of the alternative sub-
strates, and for each substrate this reduced amount of enzyme was used in the calculations. (5)
X”e (conjugated and extracellular product) and X”be (conjugated and extracellular product
from the background reactions) were introduced to be able to measure the amount of metabo-
lites eliminated by ABCIII. (6) A new aspect, a flexible description of cellular fitness was imple-
mented using SBML parameters and events (S1 Text, S5–S6 Tables). (7) The ABCIII
dimerization step was eliminated, since members of the ABCC family, participating in this
Phase are full transporters. (8) MRP and AhR were renamed to ABCIII and NR, respectively to
emphasize that they represent a general Phase III ABC transporter (e.g. MRP1, MRP2) and a
general xenobiotic nuclear receptor, respectively. Other components related to the regulation
by NR were also renamed.
Calculation of cellular fitness
In order to simulate the impact of toxic species on cellular fitness, the model was extended with
the variable Fitness (Fig. 5). To describe the toxicity of a drug or metabolite, its Critical concentra-
tion was defined as the threshold concentration, which must be exceeded to cause cellular dam-
age when the given compound is assumed to form the sole toxic species in the cell. In addition to
the inherent toxicity, the concentration and exposure time of toxic species also have to be consid-
ered for the assessment of cellular damage. To take the respective concentrations into account,
the concentration of each toxic compound is divided by its Critical concentration and a nonlinear
function of the sum of these fractions is defined as the Chemical load. Chemical load expresses
chemical stress coming from all toxic species as a single value at any given time point.
The ability of the cells to recover from moderate damage caused by chemical stress is mod-
eled by introducing a constant Regeneration capacity. According to the model, the cell can be
in one of three states, defined by relations between Chemical load, Regeneration capacity, and
Fitness.When Chemical load is lower than Regeneration capacity, repair mechanisms can com-
pensate chemical stress, the cell may recover from previous damage. If Fitness is maximal, no
regeneration occurs, since the cell is already in perfect shape. When Fitness is below its maxi-
mum, the cell undergoes regeneration to increase Fitness.When the Chemical load exceeds Re-
generation capacity, repair mechanisms are insufficient to compensate chemical stress, the cell
undergoes damage, Fitness is decreasing. The rate of regeneration and damage is the function
of Chemical load. Thus, the exposure time is also taken into account in damage calculation. Re-
generation and damage are described by the variables Regeneration and Damage, respectively.
Since cellular fitness is always the overall result of damage and regeneration, Fitness is calcu-
lated by adding the (scaled) positive values of Regeneration and the (scaled) nonpositive values
of Damage to the maximal value of Fitness. At the start of the simulation experiment, Fitness
has its maximal value (1), which represents the state of perfect health. Minimal Fitness (0) rep-
resents a state when the cell dies due to severe damage. Three characteristically different Fitness
profiles are shown in S2 Fig. A more technical description of Fitness calculation is provided as
Supporting information (S1 Text, S5–S6 Tables).
Results
We have generated a new reaction kinetic model of the cellular chemoimmune network, based
on the model proposed by Zhang et al. [20]. The Zhang-model was created to investigate
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hormesis, which was demonstrated through the function of participants of Phase I-III metabo-
lism. Since our aim was to study the network as a whole system under a wider range of drug
concentrations and various toxicity conditions, we have implemented several changes
and additions.
A simplified view of the chemoimmune model is shown in Fig. 1 (a more detailed descrip-
tion is provided in S1 Fig.). The model describes the interaction of a general xenobiotic com-
pound (X) with a cell. The extracellular concentration of the xenobiotic ([Xe]) is set to a
constant value, based on the assumption that the extracellular space contains many orders of
magnitude more X than the cell (at the end of the 60 hour long simulations in Fig. 2 the ratio of
the cumulated drug intake and the total amount of drug in the extracellular space is in the
range of 10–7), thus the amount of xenobiotic metabolized by the cell is negligible compared to
the total available amount. The xenobiotic molecule enters the cell by diffusion through the
plasma membrane. To model Phase 0 extrusion at “the gates” by plasma membrane ABC trans-
porters such as ABCB1/MDR1, ABCC1/MRP1 or ABCG2/BCRP, we introduced ABC0, which
eliminates Xc, that is the unmetabolized, cytoplasmic form of the xenobiotic, thus limiting in-
tracellular drug concentrations. Xc may also be converted to an oxidized metabolite (X’c) by
CYP, or may bound to a nuclear receptor (forming XNRc), or may be distributed to the nucleus
(Xn) by diffusion. X’c is conjugated by GST to form a more water-soluble metabolite (X”c),
which is in turn eliminated by ABCIII (modeling Phase III efflux transporters) from the cell.
It should be noted that in the model of Zhang et al. X’c represented not only the oxidized xe-
nobiotic under investigation, but also reactive species (e.g. free radicals), produced by the basal
metabolism of the cell. Since we focus on the effect of the xenobiotic and its metabolites, we in-
troduced X’bc and X”bc to separately track background reactive species and their conjugated
Fig 1. Simplified wiring diagram of the chemoimmune network model.Modeled interactions of a single
xenobiotic (X) with Phase 0-III effector enzymes and regulators. Solid arrows represent transport through
membranes or biochemical reactions. Dashed arrows denote regulation including multi-step transcriptional
and translational regulation (gray) and more direct interaction (black), such as binding of a drug to nuclear
receptors. ABC0 and ABCIII symbolize general Phase 0 and Phase III efflux transporters, respectively. CYP
and GST represent a Phase I oxidase (a member of the cytochrome P450 superfamily) and a Phase II GSH
transferase, respectively. NR symbolizes a general xenobiotic nuclear receptor, while Nrf2 denotes a specific
transcription factor. (GST, ABCIII and Nrf2 are duplicated to increase clarity of the figure. Regulatory arrows
are not duplicated.) Letters ‘c’ and ‘e’ indicate cytoplasmic and extracellular localization, respectively. X’c is
the CYP-oxidized cytoplasmic metabolite of Xc. X”c is the glutathione-conjugated form of X’c. X’bc represents
reactive species produced by normal cell metabolism. X’bc is metabolized by the same pathway as X’c.
Negative feedback loops are Xc! NR! CYP—| Xc, X’c (and X’bc)!Nrf2!GST—| X’c (and X’bc), Xc!
NR! ABC0 —| Xc, Xc! NR! Nrf2! ABC0 —| Xc, where! denotes activation and—| denotes inhibition.
Feedforward loops are Xc! NR!GST—| X’c, Xc! NR! ABCIII—| X”c (‘direct’ regulation) and Xc! NR!
Nrf2!GST—| X’c, Xc! NR! Nrf2! ABCIII—| X”c (‘indirect’ regulation). For the complete wiring diagram
with all details see S1 Fig.
doi:10.1371/journal.pone.0115533.g001
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forms, respectively. This distinction allows the separate monitoring of the amount of xenobiot-
ic metabolites and those produced by background processes. The intracellular forms of the xe-
nobiotic (Xc, Xn, X’c, X”c) and the endogenous metabolites (X’bc and X”bc) have distinct
toxicity parameters, reflecting the respective toxicity of each metabolite.
Transcriptional and translational modulation of the effector transporters and metabolic en-
zymes in the cell is significantly affected by detailed regulatory circuits. In order to describe
these processes the model contains a nuclear receptor, NR and the Nrf2 (NFE2L2) transcrip-
tion factor [26]. NR provides a model for promiscuous nuclear receptors recognizing a wide
range of drugs and xenobiotics. Since these regulatory elements interact with Xc, X’c and X’bc,
the system contains multiple feedback and feedforward loops. The complete wiring diagram of
the model is shown in S1 Fig.
Biochemical reactions of the modeled species are mathematically described by applying the
laws of biochemical reaction kinetics. The resulting set of ordinary differential equations, their
parameters and initial conditions together form the mathematical model. Since these differen-
tial equations are mostly nonlinear equations and cannot be solved analytically, numeric inte-
gration is required to solve them.
The kinetic model recapitulates basic properties of the chemoimmune
system
We performed simulations to investigate the basic behavior of the modeled network. First, the
effect of extracellular xenobiotic concentrations on the expression levels of the network ele-
ments and the cellular concentrations of the produced metabolites were studied. Second, levels
of various components were monitored as a function of the cellular uptake properties of the
Fig 2. Effect of extracellular drug concentration on the level of network components. Six time course simulations were run from steady state as
described in Methods. At t0 = 0 h the addition of drug was simulated by setting the extracellular drug concentration ([Xe]) to a constant positive value between
1 nM and 10 μM. a-c Concentration profile of the cytoplasmic form of the drug ([Xc]), its CYP-oxidized metabolite ([X’c]) and GST-conjugated form ([X”c]). d n
(X”e)/n(Xin) ratio, where n(X”e) is the amount of the ABCIII-excreted extracellular form of X” and n(Xin) is the amount of drug intake. (Details of drug intake
calculation are provided in S1 Text.) e-h Concentration profile of four key enzymes (ABC0, CYP, GST and ABCIII).
doi:10.1371/journal.pone.0115533.g002
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xenobiotic (by changing the passive diffusion rate). Third, the impact of changes in the affini-
ties of a metabolic enzyme (GST) and a transporter (ABC0) to their substrates were followed.
As expected, increasing the extracellular xenobiotic concentration ([Xe]) resulted in an in-
creased cytoplasmic concentration of the xenobiotic ([Xc]) and its oxidized ([X’c]) and con-
jugated ([X”c]) forms in the time course simulations (Fig. 2A-C). Following extracellular
xenobiotic administration at 0 h, [Xc] usually reaches a quasi-steady state level in seconds.
Due to ABC0 activity, this level is always lower than the corresponding extracellular xenobiotic
concentration. Xc triggers a regulatory response, which results in increasing ABC0 levels and
monotonically decreasing [Xc] on an hourly scale (Fig. 2A).
At relatively low xenobiotic doses, levels of X’c and X”c show a transient increase (at ca.
0–10 hours), before starting to decrease at 5 to 10 hours (Fig. 2B, C). This behavior is the result
of multiple effects. First, Xc and X’c upregulate the expression of transporters and metabolic en-
zymes (Fig. 2E-H). Initially, the CYP level grows faster than the GST level (compare Fig. 2F
and G). As a result, the production rate of X’c increases faster than its consumption rate, which
results in the increase of [X’c]. Faster consumption of Xc by CYP at the same time leads to the
faster decrease of [Xc]. Decreasing Xc concentrations slow down the production of X’c by de-
creasing the reaction rate of the CYP-catalyzed oxidation and by transcriptional and transla-
tional downregulation of CYP.
Interestingly, considering a wide range of extracellular xenobiotic concentrations, two
characteristically different X’c and X”c concentration profiles can be distinguished (Fig. 2B, C).
At lower xenobiotic doses, the transient concentration increase is moderate, as described
above. When applying higher xenobiotic concentrations, X”c levels reach a maximum, due to
the saturation of GST (Fig. 2C). Since saturation of CYP happens only at higher substrate levels
compared to GST, the oxidized xenobiotic accumulates, resulting very high X’c concentrations
(Fig. 2B).
Cellular accumulation of metabolites—an important factor in drug action—can also be in-
ferred by calculating the ratio of the amount of the ABCIII-excreted extracellular metabolite
(n(X”e)) and the amount of cumulated xenobiotic intake (n(Xin)) (Fig. 2D). At lower doses, the
n(X”e)/n(Xin) ratio is close to 100%, suggesting that most of the xenobiotic molecules are elimi-
nated from the cell. Conversely, at higher xenobiotic concentrations this ratio drops signifi-
cantly during the first hours of the simulation, which indicates severe metabolite accumulation.
It is important to note that the concentration of Xc is mostly in the nanomolar, while con-
centrations of X’c and X”c are in the micromolar range (Fig. 2A-C). This difference originates
from the high capacity of CYP, producing X’c. Parameters of conjugation are based on experi-
mental evidence, while parameters of oxidation were set by assuming CYP is not easily saturat-
ed. Since this enzyme catalyzes a practically irreversible reaction, and X’c has no other way to
be converted back to Xc, in our model the consumed Xc can only be supplemented from other
processes, which are the diffusion from the extracellular space (infinite source) and the nucleus,
and dissociation from various complexes containing the unmetabolized form of X. Taking to-
gether, the model suggests that CYP activity can easily lead to X’c concentrations orders of
magnitude higher than the concentration of Xc.
Role of individual components in detoxication
The impact of individual components was studied by selectively altering the respective kinetic
parameters. Increasing the passive diffusion rate of the xenobiotic through the membranes
(which can reflect e.g. increased hydrophobicity of the xenobiotic) results in elevated cyto-
plasmic xenobiotic concentrations ([Xc]) and—to a smaller extent—in elevated metabolite (X’c
and X”c) concentrations (Fig. 3A-D). When the diffusion rate is high, xenobiotic extrusion by
Kinetics of Metabolism in the Chemoimmune System
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ABC0 cannot significantly limit xenobiotic entry (Fig. 3A). Therefore, even though the concen-
tration of Xc is much lower than the concentration of X’c, higher diffusion rates (or the pres-
ence of uptake transporters) potentially have severe adverse effects in the cell. Thus, similar to
the case of high extracellular xenobiotic concentration (Fig. 2A, B), at high diffusion rates the
saturation of GST leads to extremely high X’c concentrations (Fig. 3A, B). These results high-
light the relevance of xenobiotic diffusion rates in pharmacology, and also suggest that the in-
corporation of uptake transporters into the model could open further perspectives in
understanding the kinetics of cellular xenobiotic metabolism [27]
We simulated the consequence of increased ABC0–mediated xenobiotic efflux by decreasing
the apparent Michaelis constant (Km; Fig. 3E-H). In case of moderate substrate concentrations,
lower Km values result in increased efflux, which leads to lower [Xc], and consequently also to
reduced metabolite (X’c and X”c) concentrations. As expected, the increased diffusion rate can
be compensated by an increase in the affinity of ABC0 (S3 Fig.). Similarly, by lowering the Km
of GST, X’c concentrations decrease (Fig. 4B), while X”c levels increase due to the higher pro-
duction rate (Fig. 4C).
Interestingly, our model predicts that reactive species produced by normal cell metabolism
(X’bc) may play an important role in preconditioning the chemoimmune system. Decreased af-
finity of GST to X’bc (increased Km) results in elevated baseline concentrations of X’bc, which in
turn leads to increased baseline ABC0 levels (since X’bc upregulates ABC0 through the Nrf2
pathway), even in the absence of extracellular xenobiotics. (Compare basal ABC0 levels at t = 0 h
on Fig. 4H which are steady state values calculated before simulating the addition of the xeno-
biotic to the system.) The baseline ABC0 level has a twofold significance. As expected, ABC0
function results in lower Xc levels (Fig. 4A, E). In addition, when higher xenobiotic doses are
Fig 3. Effect of diffusion rate and ABC0 affinity to drug on the level of network components. Time course simulations were run from steady states
belonging to different parameter sets as described in Methods. The extracellular drug concentration ([Xe]) was set to 75 nM at t0 = 0 h. Parameter values are
expressed as multiples of their default value (S3 Table). Concentration profile of Xc, X’c, X”c and the level of ABC0 were plotted. a-d Effect of diffusion rate
through membranes. Five simulations were run by setting the diffusion rate constants to different values of four orders of magnitude. e-h Effect of ABC0
affinity to drug (Km). Five simulations were run by setting the Michaelis constant to different values encompassing four orders of magnitude.
doi:10.1371/journal.pone.0115533.g003
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applied, increased baseline ABC0 activity protects the cells against initial [X’c] peaks (Fig. 4F).
Thus, the presence of reactive species (e.g. free radicals) increases the initial detoxication perfor-
mance of the cell. This feature of the system can be viewed also as a hallmark of hormesis: moder-
ate stress may be beneficial for the cell to react faster during the need of chemodefense [28].
Model of cellular fitness to study toxicity
In addition to describing changes in the concentration of intracellular xenobiotic forms, we
wished to model the cytotoxic effect of the compounds. To this end we extended the model
with a versatile description of the impact of toxic species on cellular fitness (Fig. 5), described
by the variable Fitness (blue curve). This is a general description which does not contain any as-
sumption about the mechanism of toxicity, and should be considered as an approximation
rather than a detailed representation of toxic effects.
Typical toxicity studies use only single parameters (e.g. EC50, LD50), and are not informative
regarding the toxicity of the various intracellular drug forms. In our model, we have assigned a
toxicity parameter to each intracellular form of the xenobiotic, and indirectly calculated an
overall EC50-like value, allowing the simulation of toxic effects of drugs with different ‘toxicity
profiles’. See Methods for implementation details of Fitness‘ calculation.
In silico cytotoxicity curves
In order to test one of the possible practical applications of the kinetic model, we aimed to cal-
culate drug cytotoxicity curves. The analogous diagrams in the model areMinimal Fitness vs
Fig 4. Effect of external drug concentration and GST affinity on the level of network components. Time course simulations were run from steady
states belonging to different parameter sets as described in Methods. The Michaelis constants describing the affinity of GST to its substrates (X’c and X’bc)
were set to five different values encompassing four orders of magnitude. Parameter values are expressed as multiples of their default value (S3 Table).
Concentration profile of Xc, X’c, X”c and the level of ABC0 were plotted. a-d The effect of GST affinity to its substrates (Km values) at lower extracellular
xenobiotic concentrations. [Xe] was set to 75 nM at t0 = 0 h. e-h The effect of GST affinity to its substrates at higher extracellular xenobiotic concentrations.
[Xe] was set to 300 nM at t0 = 0 h.
doi:10.1371/journal.pone.0115533.g004
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[Xe] curves, generated by running multiple time course simulations, by using increasing extra-
cellular xenobiotic concentrations and measuring the minimal Fitness values in 48 hours (the
length of a typical in vivo cytotoxicity test) (Fig. 6).Minimal Fitness is used instead of the
Fitness value belonging to the endpoint of the simulation, as the final value reflects the actual
state of the cell and does not include information on decreased metabolism (e.g. cell division),
which is measured in in vivo experiments. Therefore, similar to an experimental cytotoxicity
curve, an in silico cytotoxicity curve also allows the deduction of the EC50 value: it can be de-
fined as the external xenobiotic concentration which causes 50% decrease of Fitness in the time
course of 48 hours.
An important difference between experimentally determined and in silico cytotoxicity
curves is that the former is calculated by investigating a cell population, and the latter is calcu-
lated by deterministic modeling of a hypothetical single cell. In the theoretical case, minimal
Fitness values between 1 and 0 can be interpreted like partial growth inhibition, and zero
Fitness as cell death.
First, we investigated the impact of the toxicity of the unmetabolized form ([Xc,crit]) on the
in silico cytotoxicity curve (Fig. 6A). Assuming that X’c is more toxic than X”c (this is the typi-
cal case) the critical concentrations of X’c and X”c were set to constant values of 1 μM and
100 μM, respectively. The critical concentration of Xc was varied between 0.05 nM and 5 μM.
When [Xc,crit] = 0.05 nM, and Xc is more toxic than X’c, the corresponding curve was shifted to
lower concentrations (EC50 = 4.38 nM) from the curve with [Xc,crit] = 0.5 nM (EC50 = 25.72 nM).
Contrary, when [Xc,crit] = 5 μM, and Xc is less toxic than X’c, the corresponding curve was
shifted to higher concentrations (EC50 = 47.97 nM). The curves with [Xc,crit] = 5 nM and
5 μM are close to each other, indicating a maximal EC50 threshold close to [Xe] = 53 nM. The
Fig 5. Modeling cellular fitness to study cytotoxic effects.Calculation of cellular fitness by assuming a
single toxic compound, X. Cytoplasmic concentration of the drug ([Xc]) was calculated using the time course
simulation described in Methods. Critical concentration of Xc ([Xc,crit], dashed yellow line) was defined as
the threshold concentration, which must be exceeded to cause cellular damage.Chemical load is defined
as a nonlinear function of the [Xc]/[Xc,crit] ratio (magenta curve). The cell is assumed to have a constant
Regeneration capacity (dashed black line). WhenChemical load exceeds Regeneration capacity (t0< t< t1),
the cell undergoes damage. Cellular damage is represented by the Damage variable (red curve), which has
nonpositive values proportional to the light red shaded area. WhenChemical load is below Regeneration
capacity and Fitness is below of its maximal value (t1< t< t2), the cell undergoes regeneration. Regeneration
is represented by theRegeneration variable (green curve), which has nonnegative values proportional to the
green shaded area. WhenChemical load is below Regeneration capacity but Fitness is maximal (t2< t), nor
damage, neither regeneration occurs. Fitness (blue curve) is calculated by adding the (scaled) nonnegative
values ofRegeneration and the (scaled) nonpositive values ofDamage to the maximal value of Fitness. See
text for details.
doi:10.1371/journal.pone.0115533.g005
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Fig 6. In silico cytotoxicity curves reveal impact of drug’s toxicity profile and protein level on survival.
Time course simulations were run for up to 48 hours from steady states belonging to different parameter sets
and extracellular drug concentrations ([Xe], set at t0 = 0 h) as described in Methods. The minimal Fitness
values reached in simulations were plotted against [Xe] (colored circles; connected by interpolation curves—
see S1 Text). Critical concentrations of X’c and X”c are constant on all panels with values 1 μM and 100 μM,
respectively. Critical concentration of Xc ([Xc,crit]) is indicated on the panels. a Impact of the toxicity of the
unmetabolized form of the drug ([Xc,crit]) on in silico cytotoxicity. In silico cytotoxicity curves were plotted for
[Xc,crit] values from 0.05 nM to 5 μM. The EC50 value is indicated for [Xc,crit] = 0.5 nM. b Impact of transporter
and oxidase levels on in silico cytotoxicity when Xc is more toxic than X’c ([Xc,crit] = 0.05 nM). c Impact of
transporter and oxidase levels on in silico cytotoxicity when Xc is less toxic than X’c ([Xc,crit] = 5 μM). In panels
b and c in silico cytotoxicity curves were calculated after setting the transcription rates of ABC0 or CYP 0.2 or
5 times of its original value (S3 Table) to model lower or higher expression levels.
doi:10.1371/journal.pone.0115533.g006
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existence of the threshold can be explained as follows: when [Xe] is above this threshold, [X’c]
exceeds [X’c,crit] during a long period of time, resulting in cell death.
Next, we investigated the influence of altered levels of ABC0 and CYP in two cases of differ-
ent toxicity conditions. In the first case the drug is more toxic than its oxidized metabolite.
This is a typical scenario, e.g. most docetaxel metabolites are more than 500 times less toxic
than the drug itself [29]. In the opposite case the drug is less toxic than its oxidized metabolite.
Among the important examples are antitumor prodrugs like cyclophosphamide [12]. As ex-
pected, when the ABC0 substrate Xc is more toxic than X’c, changes in ABC0 levels lead to
much more pronounced effects than changes in CYP expression levels (Fig. 6B). Decrease of
ABC0 level results in lower EC50 values, while an increase of ABC0 level results in higher EC50
values. However, when Xc is less toxic than X’c (Fig. 6C), the effect of CYP modulation is more
significant. Modulation of ABC0 is still important, since it indirectly influences the X’c level. In
this case both decrease of ABC0 and increase of CYP levels results in lower EC50 values, while
increase of ABC0 and decrease of CYP level results in higher EC50 values. These results are in
agreement with RNA silencing experiments, where cytotoxicity to doxorubicin increased after
silencing of ABCG2 [22], whereas cytotoxicity to cyclophosphamide decreased after the silenc-
ing of CYP3A4 [21].
Discussion
In order to analyze the cellular chemoimmune network from a systems biology perspective, we
have developed a detailed reaction kinetic model. Our model is the first to describe the metabo-
lism of a single, general xenobiotic or drug covering all aspects of cellular detoxication from
Phase 0 to Phase III and reflecting xenobiotic dependent transcriptional regulation. In addition
to effectors (transporters and metabolic enzymes converting chemicals) the kinetic model also
contains regulatory elements, including a general xenobiotic sensing nuclear receptor, the
Keap1–Nrf2 oxidative stress response pathway, and sophisticated transcriptional and transla-
tional regulatory circuits. These pathways form multiple feedback and feedforward loops,
through which the xenobiotic and its oxidized metabolite regulate their own transport and me-
tabolism. Of course, any of these regulatory mechanisms are independently switchable by set-
ting the appropriate reaction kinetic parameters. This way modeling the metabolism of
xenobiotics e.g. without Phase 0 excretion is also possible.
The chemoimmune model recapitulates basic properties of the chemoimmune system. In-
creasing extracellular xenobiotic concentrations result in increased cytoplasmic concentrations
of the xenobiotic metabolites, which in turn lead to the upregulation of transporters and meta-
bolic enzymes through transcriptional and translational feedback and feedforward loops
(Fig. 2). The cytoplasmic concentration of the unmetabolized xenobiotic is jointly affected by
its diffusion rate, Phase 0 transporter activity and consumption by metabolic processes (Fig. 3).
We find that increased affinity (decreased Km) of a Phase 0 xenobiotic transporter for the xeno-
biotic can counteract increased xenobiotic influx (increased rate of diffusion) (S3 Fig.).
In various time course simulations the concentrations of the xenobiotic, its metabolites,
metabolic enzymes and efflux transporters were followed and relevant scenarios corresponding
to particular drug effects were studied. Simulations clearly indicate that the metabolites can
reach much higher concentrations than the external xenobiotic concentration especially when
an enzyme, which forms a bottleneck in the metabolic pathway is saturated, thus leading to an
extremely elevated concentration of its substrate (Fig. 2). An example of this feature in our
model is GST, which conjugates GSH to the oxidized form of the xenobiotic. Since the oxidized
form neither can be reverted back to reduced form, nor can be removed by other pathways, sat-
uration of GST leads to an extreme increase in the level of the oxidized form (Fig. 2B, D). In a
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real cell, the oxidized form may be cleared by pathways other than GSH conjugation. On the
contrary, the unmetabolized form of the xenobiotic cannot be concentrated in the cell, since
even in the case of limited oxidase (CYP) action, it still can be cleared at Phase 0 due to ABC
transporter action. The model suggests that the role of Phase 0 exporters extends beyond limit-
ing the cellular entry of toxic molecules to prevent the buildup of extreme metabolite concen-
trations and the saturation of metabolic enzymes.
Interestingly, saturation of metabolic enzymes is also prevented by reactive species pro-
duced by endogenous metabolic processes of the cell. Our simulations suggest that the in-
creased levels of reactive species produced by normal cell metabolism prevent extreme
metabolite peaks (Fig. 4F) by elevating basal enzyme expression levels (Fig. 4H). Thus, a low
level exposure to toxic molecules can prepare the system for a massive attack of xenobiotics.
This characteristic of the chemoimmune system resembles the phenomenon of active immuni-
zation in the context of the immune system, making the analogy between the immune and che-
moimmune systems even more fascinating.
By means of the newly developed toxicity framework, the model became suitable to predict
toxicity parameters of in silico cytotoxicity assays (Fig. 6). The toxicity module—despite being
simplified—is able to qualitatively reproduce the results of cell killing experiments [21, 22]. An
important limitation of our model in this regard is that in order to provide predictive systemic
effects, the toxicological properties of the modeled drug metabolites have to be independently
estimated. Still, from relevant experiments these values can be reinserted into the model to
study the effects of variable cellular parameters.
An important medical aspect is the involvement of the chemoimmune network and more
specifically multidrug ABC transporters in cancer drug resistance, a major cause of the failure
of chemotherapy in malignant diseases. Potent inhibitors against ABCB1 have been developed
to overcome cancer multidrug resistance (MDR), but the therapeutic applications were unsuc-
cessful in major clinical trials [30]. These results underline the importance of ABC transporter
analysis in the context of the whole chemoimmune network [31, 32]. By providing a system
level description of this network, the chemoimmune model provides powerful means for the
comprehension of side-effects caused by ABC transporter inhibition, and may serve as a valu-
able aid in the development of novel therapeutic strategies.
In summary, the chemoimmune model describes cellular xenobiotic metabolism well at the
level of the applied simplification. In its present form, it is a capable tool for the investigation
of dynamic interactions between components of the chemoimmune system and for the assess-
ment of toxic effects on cellular viability. Also, it can serve as a basis of forthcoming, more ad-
vanced models. Introduction of xenobiotic uptake transporters (e.g. members of the SLC
family) with saturable properties as compared to passive xenobiotic diffusion, implementation
of further xenobiotic sensing nuclear receptors or further metabolic enzymes and transporters
may lead to more realistic models suitable not only for qualitative, but also for quantitative
predictions.
Supporting Information
S1 Fig. Detailed representation of the model of the chemodefense network.Wiring diagram
of the chemodefense network represented as an SBGN [33] diagram.
(PDF)
S2 Fig. Characteristic ‘Fitness profiles’ for three different external drug concentrations.
Three time course simulations were ran from steady state as described in Methods after setting
different extracellular drug concentrations ([Xe]) at t0 = 0 h. Critical concentration of Xc, X’c
and X”c was set to 5 nM, 5 μM and 5 mM, respectively (S3 Table). Concentration of X’c (solid
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curves), and Fitness (dashed curves) were plotted. Simulating drug administration by setting
relatively low external drug concentration (green curves) results only in transient Fitness de-
crease, since decreasing concentration of toxic compounds allows regeneration. Moderate drug
concentration (blue curves) leads to monotonic Fitness decrease to an intermediate level till the
end of the simulation experiment. Considering that typical cytotoxicity tests are run up to 24
or 48 hours, the observed behavior can be interpreted as the sign of cytostasis or partial growth
inhibition. When applying relatively high drug concentration (red curves), Fitness decreases to
zero before the end of the experiment, which signs the death of the cell. When the cell dies, sim-
ulation is interrupted.
(PDF)
S3 Fig. Simultaneous alteration of diffusion rate and ABC0 affinity to drug can compensate
each other’s effect. Five time course simulations were run from steady states belonging to dif-
ferent parameter sets as described in Methods. The Michaelis constant of ABC0 and the diffu-
sion rate constants were altered simultaneously. The extracellular drug concentration ([Xe])
was set to 75 nM at t0 = 0 h. Similarity of concentration profiles indicate that opposing effects
affecting xenobiotic transport through membranes can compensate each other. Parameter val-
ues are expressed as multiples of their default value (S3 Table) a-c Concentration profile of the
cytoplasmic form of the drug ([Xc]), its CYP-oxidezed metabolite ([X’c]) and the GST-conju-
gated form of the latter ([X”c]). d Concentration profile of ABC0.
(PDF)
S1 Model. Mathematical model. The model is provided as a separate SBML (Level 2 Version
4) format [23] file.
(XML)
S1 Table. Equations of the model. For parameters and initial values see S2 and S4 Tables, re-
spectively. Parameter names may contain colons, slashes, and parentheses as shown in S3
Table. Multiplication and division is always indicated by centered dots and fractions, respec-
tively. Equations of fitness calculation are shown in S5 Table.
(PDF)
S2 Table. Parameters of the model. SBML IDs, names, and default (wild type) values of ‘fixed’
type model parameters. For corresponding equations see S1 Table.
(XLS)
S3 Table. Parameters changed in simulation experiments. Parameters changed (compared to
their default values shown in S2 Table) in simulation experiments.
(PDF)
S4 Table. Initial values of the model. SBML IDs, species’ names, species’ compartments, and
initial values. For corresponding equations see S1 Table.
(XLS)
S5 Table. Mathematical details of cellular fitness calculation. SBML parameter types: F:
fixed, A: assignment, O: ODE, B: Boolean (fixed with values 0 and 1, set by events), E: fixed, set
by events. Min. and Max. values in parentheses indicate the actual values of minimums and
maximums, respectively. For events see S6 Table.
(PDF)
S6 Table. SBML events used in cellular fitness calculation. For variable names see S5 Table.
(PDF)
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